Listed

Allarity Therapeutics, Inc.

ALLRNasdaqCIK 1860657HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$2.7m, Q2 FY2026
Net income−$3.4m, Q2 FY2026
Allarity Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figurenot reportednot reported0.0Revenue, Q1 FY2026, three months to 2026-03-31$25.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Gross profit$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m1.9Research and development, Q3 FY2023, three months to 2023-09-30$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure2.6Research and development, Q4 FY2023, three months to 2023-12-31$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001437749-25-010198. Derived: 12-month figure less the 9-month figure.Report this figure2.2Research and development, Q1 FY2024, three months to 2024-03-31$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure1.1Research and development, Q2 FY2024, three months to 2024-06-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure1.0Research and development, Q3 FY2024, three months to 2024-09-30$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure1.8Research and development, Q4 FY2024, three months to 2024-12-31$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure1.4Research and development, Q1 FY2025, three months to 2025-03-31$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure2.3Research and development, Q2 FY2025, three months to 2025-06-30$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure1.2Research and development, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure1.7Research and development, Q4 FY2025, three months to 2025-12-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure1.3Research and development, Q1 FY2026, three months to 2026-03-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure1.3Research and development, Q2 FY2026, three months to 2026-06-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Operating income$m(4.4)Operating income, Q3 FY2023, three months to 2023-09-30−$4.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure(4.9)Operating income, Q4 FY2023, three months to 2023-12-31−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001437749-25-010198. Derived: 12-month figure less the 9-month figure.Report this figure(4.2)Operating income, Q1 FY2024, three months to 2024-03-31−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure(3.4)Operating income, Q2 FY2024, three months to 2024-06-30−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure(12.3)Operating income, Q3 FY2024, three months to 2024-09-30−$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure(7.3)Operating income, Q4 FY2024, three months to 2024-12-31−$7.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure(3.0)Operating income, Q1 FY2025, three months to 2025-03-31−$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure(4.1)Operating income, Q2 FY2025, three months to 2025-06-30−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure(2.5)Operating income, Q3 FY2025, three months to 2025-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure(2.9)Operating income, Q4 FY2025, three months to 2025-12-31−$2.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure(2.7)Operating income, Q1 FY2026, three months to 2026-03-31−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure(2.7)Operating income, Q2 FY2026, three months to 2026-06-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$34.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure0.2Interest expense, Q4 FY2023, three months to 2023-12-31$230.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-08, accession 0001213900-24-020864. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2024, three months to 2024-03-31$102.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure0.4Interest expense, Q2 FY2024, three months to 2024-06-30$426.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure0.1Interest expense, Q3 FY2024, three months to 2024-09-30$50.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure0.1Interest expense, Q4 FY2024, three months to 2024-12-31$75.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2025, three months to 2025-03-31$57.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$12.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure0.1Interest expense, Q3 FY2025, three months to 2025-09-30$57.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure0.1Interest expense, Q4 FY2025, three months to 2025-12-31$59.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2026, three months to 2026-03-31$229.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.7Interest expense, Q2 FY2026, three months to 2026-06-30$719.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure0.1Income tax, Q4 FY2023, three months to 2023-12-31$83.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-31, accession 0001437749-25-010198. Derived: 12-month figure less the 9-month figure.Report this figure(0.0)Income tax, Q1 FY2024, three months to 2024-03-31−$4.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure(0.4)Income tax, Q3 FY2024, three months to 2024-09-30−$377.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Net income$m(4.4)Net income, Q3 FY2023, three months to 2023-09-30−$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure(1.7)Net income, Q4 FY2023, three months to 2023-12-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001437749-25-010198. Derived: 12-month figure less the 9-month figure.Report this figure(3.8)Net income, Q1 FY2024, three months to 2024-03-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure(1.6)Net income, Q2 FY2024, three months to 2024-06-30−$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure(11.6)Net income, Q3 FY2024, three months to 2024-09-30−$11.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure(7.5)Net income, Q4 FY2024, three months to 2024-12-31−$7.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure(2.7)Net income, Q1 FY2025, three months to 2025-03-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure(2.3)Net income, Q2 FY2025, three months to 2025-06-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure(2.8)Net income, Q3 FY2025, three months to 2025-09-30−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure(3.4)Net income, Q4 FY2025, three months to 2025-12-31−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure(2.8)Net income, Q1 FY2026, three months to 2026-03-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure(3.4)Net income, Q2 FY2026, three months to 2026-06-30−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Diluted EPS$ per share(2.03)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$2.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figurenot reported(22.14)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$22.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure(0.11)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Basic EPS$ per share(1346.09)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1346.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figurenot reported(664.16)Basic EPS, Q1 FY2024, three months to 2024-03-31−$664.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure(3.34)Basic EPS, Q2 FY2024, three months to 2024-06-30−$3.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure(7.71)Basic EPS, Q3 FY2024, three months to 2024-09-30−$7.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figurenot reported(0.25)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure(0.15)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure(0.19)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figurenot reported(0.17)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure(0.21)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure

Balance sheet

Cash and equivalents$17.0m, Q2 FY2026
Long-term debt$2.7m, FY2023
Shareholders' equity$3.5m, Q2 FY2026
Allarity Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m1.4Cash and equivalents, Q3 FY2023, at 2023-09-30$1.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure0.2Cash and equivalents, FY2023, at 2023-12-31$166.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001437749-25-010198.Report this figure0.3Cash and equivalents, Q1 FY2024, at 2024-03-31$312.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure19.2Cash and equivalents, Q2 FY2024, at 2024-06-30$19.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figurenot reported19.5Cash and equivalents, FY2024, at 2024-12-31$19.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001437749-26-010310.Report this figure25.2Cash and equivalents, Q1 FY2025, at 2025-03-31$25.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure17.8Cash and equivalents, Q2 FY2025, at 2025-06-30$17.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure16.9Cash and equivalents, Q3 FY2025, at 2025-09-30$16.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure14.7Cash and equivalents, FY2025, at 2025-12-31$14.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure19.8Cash and equivalents, Q1 FY2026, at 2026-03-31$19.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure17.0Cash and equivalents, Q2 FY2026, at 2026-06-30$17.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Current assets$m4.4Current assets, Q3 FY2023, at 2023-09-30$4.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure2.0Current assets, FY2023, at 2023-12-31$2.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001437749-25-010198.Report this figure2.3Current assets, Q1 FY2024, at 2024-03-31$2.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure21.3Current assets, Q2 FY2024, at 2024-06-30$21.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figure20.4Current assets, Q3 FY2024, at 2024-09-30$20.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure22.3Current assets, FY2024, at 2024-12-31$22.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001437749-26-010310.Report this figure29.4Current assets, Q1 FY2025, at 2025-03-31$29.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure20.9Current assets, Q2 FY2025, at 2025-06-30$20.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure20.5Current assets, Q3 FY2025, at 2025-09-30$20.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure17.9Current assets, FY2025, at 2025-12-31$17.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure34.5Current assets, Q1 FY2026, at 2026-03-31$34.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure31.7Current assets, Q2 FY2026, at 2026-06-30$31.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Total assets$m13.9Total assets, Q3 FY2023, at 2023-09-30$13.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure11.9Total assets, FY2023, at 2023-12-31$11.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001437749-25-010198.Report this figure12.0Total assets, Q1 FY2024, at 2024-03-31$12.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure30.9Total assets, Q2 FY2024, at 2024-06-30$30.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figure20.4Total assets, Q3 FY2024, at 2024-09-30$20.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure22.7Total assets, FY2024, at 2024-12-31$22.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001437749-26-010310.Report this figure29.7Total assets, Q1 FY2025, at 2025-03-31$29.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure21.2Total assets, Q2 FY2025, at 2025-06-30$21.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure20.8Total assets, Q3 FY2025, at 2025-09-30$20.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure18.3Total assets, FY2025, at 2025-12-31$18.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure34.9Total assets, Q1 FY2026, at 2026-03-31$34.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure32.1Total assets, Q2 FY2026, at 2026-06-30$32.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Current liabilities$m15.7Current liabilities, Q3 FY2023, at 2023-09-30$15.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure14.2Current liabilities, FY2023, at 2023-12-31$14.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001437749-25-010198.Report this figure18.0Current liabilities, Q1 FY2024, at 2024-03-31$18.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure10.6Current liabilities, Q2 FY2024, at 2024-06-30$10.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figure7.4Current liabilities, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure10.8Current liabilities, FY2024, at 2024-12-31$10.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001437749-26-010310.Report this figure11.1Current liabilities, Q1 FY2025, at 2025-03-31$11.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure9.0Current liabilities, Q2 FY2025, at 2025-06-30$9.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure8.8Current liabilities, Q3 FY2025, at 2025-09-30$8.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure8.4Current liabilities, FY2025, at 2025-12-31$8.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure28.0Current liabilities, Q1 FY2026, at 2026-03-31$28.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure28.6Current liabilities, Q2 FY2026, at 2026-06-30$28.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Total liabilities$m17.3Total liabilities, Q3 FY2023, at 2023-09-30$17.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure14.6Total liabilities, FY2023, at 2023-12-31$14.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001437749-25-010198.Report this figure18.4Total liabilities, Q1 FY2024, at 2024-03-31$18.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure11.0Total liabilities, Q2 FY2024, at 2024-06-30$11.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figure7.4Total liabilities, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure10.8Total liabilities, FY2024, at 2024-12-31$10.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001437749-26-010310.Report this figure11.1Total liabilities, Q1 FY2025, at 2025-03-31$11.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure9.0Total liabilities, Q2 FY2025, at 2025-06-30$9.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-15, accession 0001437749-25-027146.Report this figure8.8Total liabilities, Q3 FY2025, at 2025-09-30$8.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure8.4Total liabilities, FY2025, at 2025-12-31$8.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure28.0Total liabilities, Q1 FY2026, at 2026-03-31$28.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure28.6Total liabilities, Q2 FY2026, at 2026-06-30$28.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Long-term debt$m2.7Long-term debt, Q3 FY2023, at 2023-09-30$2.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure2.7Long-term debt, FY2023, at 2023-12-31$2.7m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-31, accession 0001437749-25-010198.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reported0.3Current portion of debt, FY2023, at 2023-12-31$250.0k. XBRL concept us-gaap:DebtCurrent. 10-K filed 2024-03-08, accession 0001213900-24-020864.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Short-term borrowings, FY2025, at 2025-12-31$0. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure20.1Short-term borrowings, Q1 FY2026, at 2026-03-31$20.1m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure20.9Short-term borrowings, Q2 FY2026, at 2026-06-30$20.9m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure
Shareholders' equity$m(3.4)Shareholders' equity, Q3 FY2023, at 2023-09-30−$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001437749-24-035314.Report this figure(2.8)Shareholders' equity, FY2023, at 2023-12-31−$2.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001437749-26-010310.Report this figure(6.5)Shareholders' equity, Q1 FY2024, at 2024-03-31−$6.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure19.8Shareholders' equity, Q2 FY2024, at 2024-06-30$19.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure13.0Shareholders' equity, Q3 FY2024, at 2024-09-30$13.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure11.8Shareholders' equity, FY2024, at 2024-12-31$11.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure18.7Shareholders' equity, Q1 FY2025, at 2025-03-31$18.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure12.2Shareholders' equity, Q2 FY2025, at 2025-06-30$12.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure12.0Shareholders' equity, Q3 FY2025, at 2025-09-30$12.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001437749-25-035003.Report this figure9.8Shareholders' equity, FY2025, at 2025-12-31$9.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure6.9Shareholders' equity, Q1 FY2026, at 2026-03-31$6.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure3.5Shareholders' equity, Q2 FY2026, at 2026-06-30$3.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure

Cash flow

Operating cash flow−$2.6m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Share repurchases$0, Q2 FY2026
Allarity Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(5,376)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001437749-24-035314. Derived: 9-month figure less the 6-month figure.Report this figure(1,672)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001437749-25-010198. Derived: 12-month figure less the 9-month figure.Report this figure(1,399)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0001437749-25-015780.Report this figure(7,304)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$7.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-15, accession 0001437749-25-027146. Derived: 6-month figure less the 3-month figure.Report this figure(5,443)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001437749-25-035003. Derived: 9-month figure less the 6-month figure.Report this figure(3,206)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure(2,686)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure(5,481)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001437749-26-027830. Derived: 6-month figure less the 3-month figure.Report this figure(3,410)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001437749-25-035003. Derived: 9-month figure less the 6-month figure.Report this figure(3,243)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure(4,493)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure(2,564)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001437749-26-027830. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001437749-26-027830. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reported64.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$64.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001437749-26-027830. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$knot reportednot reportednot reportednot reported0.0Share repurchases, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-11-14, accession 0001437749-25-035003. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure0.0Share repurchases, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure2,565Share repurchases, Q2 FY2025, three months to 2025-06-30$2.6m. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-08-14, accession 0001437749-26-027830. Derived: 6-month figure less the 3-month figure.Report this figure141Share repurchases, Q3 FY2025, three months to 2025-09-30$141.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-11-14, accession 0001437749-25-035003. Derived: 9-month figure less the 6-month figure.Report this figure484Share repurchases, Q4 FY2025, three months to 2025-12-31$484.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-03-30, accession 0001437749-26-010310. Derived: 12-month figure less the 9-month figure.Report this figure262Share repurchases, Q1 FY2026, three months to 2026-03-31$262.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-05-15, accession 0001437749-26-017371.Report this figure0.0Share repurchases, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-08-14, accession 0001437749-26-027830. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)14.98m, Q2 FY2024
Allarity Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2020-09-30period not labelled2021-06-30Q3 FY20212021-09-30Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30
Diluted shares (weighted)m shares3.7Diluted shares (weighted), period not labelled, three months to 2020-09-303,724,617 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q/A filed 2022-05-17, accession 0001213900-22-027297.Report this figure5.0Diluted shares (weighted), period not labelled, three months to 2021-06-305,017,183 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-10-07, accession 0001213900-22-062840.Report this figure7.8Diluted shares (weighted), Q3 FY2021, three months to 2021-09-307,753,051 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-14, accession 0001213900-22-072355.Report this figure0.2Diluted shares (weighted), Q1 FY2022, three months to 2022-03-31236,811 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-11, accession 0001213900-23-038609.Report this figure0.1Diluted shares (weighted), Q2 FY2022, three months to 2022-06-30120,223 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-14, accession 0001213900-23-066893.Report this figure0.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-307,153 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure0.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31528 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure0.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3018,621 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figure2.5Diluted shares (weighted), Q3 FY2023, three months to 2023-09-302,474,724 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001213900-23-086382.Report this figure0.2Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31175,266 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001213900-24-042997.Report this figure15.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3014,979,095 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-05, accession 0001213900-24-065252.Report this figure

Shares outstanding: 15.91mShares outstanding, period not labelled, at 2026-08-1415,910,724 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001437749-26-027830.Report this figure at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.